Study ID | County | Study type | Interventions | Sample size | Age (year) | Gender | Fracture type | Follow-up period | Result | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neer classification system | AO classification system | ||||||||||||
Male | Female | 2-part | 3-part | 4-part | |||||||||
Chen 2018 | China | retrospective | FSA + LCP | 47 | 68.6 | 12 | 35 |  | 12 | 35 |  | 33.5 | loss of reduction (>5 mm), functional outcomes (DASH, CMS) and complications |
 |  |  | LCP | 42 | 69.12 | 15 | 27 |  | 10 | 32 |  | 35.2 | |
Cui 2019 | China | retrospective | FSA + LCP | 25 | 73.16 | 7 | 18 |  | 17 | 8 |  | 31.56 | radiological changes in NSA and HHH, functional outcomes (DASH, CMS), ROM and complications |
 |  |  | LCP | 35 | 72.46 | 11 | 24 |  | 25 | 10 |  | 32.23 | |
Davids 2020 | America | retrospective | FSA + LCP | 27 | 59.9 (19 to 90) | total 102: male 31, female 71 | total 102: 2-part 53; 3-part 49 |  | mean 17.6 | functional outcomes (DASH, SST scores), VAS, ROM and complications | |||
 |  |  | LCP | 75 | |||||||||
Kim 2020 | South Korea; | retrospective | FSA + LCP | 34 | 73.8 ± 5.80 | 13 | 21 |  |  |  | A2 2; A3 13; B1 6; B2 11; B3 2 | 16.2 ± 3.74 | average bone union time, mean NAS, CMS, ROM and complications |
 |  | LCP | 29 | 73.8 ± 5.80 | 12 | 17 |  |  |  | A2 3; A3 11; B1 4; B2 10; B3 1 | 18.6 ± 6.77 |  | |
Lee 2019 | South Korea | retrospective | FSA + LCP | 45 | 75.6 (55 to 87) | 12 | 33 | 21 | 20 | 4 |  | 13.6 (12 to 17) | radiological changes in NSA and HHH, functional outcomes (DASH, CMS), VAS, ROM and complications |
 |  | LCP | 52 | 73.3 (52 to 89) | 14 | 38 | 25 | 22 | 5 |  | 14.2 (12 to 19) |  | |
Wang 2019 | China | retrospective | FSA + LCP | 39 | 72.2 ± 5.9 | 16 | 23 |  |  | 39 |  | 19 (12 to 34) | the final CCD angle, functional outcome (ASES) and complications |
 |  |  | FSA + LCP | 43 | 72.7 ± 5.6 | 14 | 29 |  |  | 43 |  |  |  |
 |  |  | LCP | 46 | 72.5 ± 5.0 | 13 | 33 |  |  | 46 |  |  |  |
Zhao 2019 | China | retrospective | FSA + LCP | 21 | 68.8 ± 6.3 | 11 | 10 |  | 14 | 7 |  | 12 | radiological changes in NSA and HHH, functional outcomes (CMS, ASES, DASH), VAS and complications |
 |  |  | LCP | 21 | 69.0 ± 7.2 | 12 | 9 |  | 15 | 6 |  | 12 |  |
Tuerxun 2020 | China | retrospective | FSA + LCP | 41 | 64.1(34 to 89) | 12 | 29 | 6 | 19 | 16 |  | 16.3 | radiological changes in NSA and HHH, functional outcomes (CMS) and complications |
 |  |  | LCP | 22 | 64.1(35 to 83) | 9 | 13 | 3 | 10 | 9 |  | 16.3 |  |